A Phase 2, Pilot Open Label, Sequential Group, Investigator Blinded Study of Magnetic Resonance Spectroscopy (31P-MRS) to Assess the Effects of CNM-Au8 for the Bioenergetic Improvement of Impaired Neuronal Redox State in Amyotrophic Lateral Sclerosis
Latest Information Update: 28 Jan 2022
At a glance
- Drugs CNM Au8 (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Therapeutic Use
- Acronyms REPAIR-ALS
- Sponsors Clene Nanomedicine
Most Recent Events
- 11 Jan 2022 Planned End Date changed from 1 Jul 2022 to 1 Mar 2022.
- 11 Jan 2022 Planned primary completion date changed from 1 Apr 2022 to 1 Feb 2022.
- 11 Jan 2022 Planned initiation date changed from 30 Apr 2021 to 1 Mar 2020.